secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001193125-24-079597
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd reports FY2023 net loss $198.6M; obtains EUA for PEMGARDA COVID-19 PrEP
-------------------------------------------------------------------------------

- Net loss $198.6M ($1.81/share) vs $241.3M ($2.23/share) in 2022; R&D expenses $163.6M.
- Cash & equivalents $200.6M as of Dec 31, 2023; expects runway into Q4 2024 (excl. PEMGARDA sales).
- Received EUA on Mar 22, 2024 for PEMGARDA (pemivibart) for COVID-19 PrEP in immunocompromised patients.
- Raised $40.5M in gross proceeds from ATM facility in Feb 2024 to strengthen balance sheet ahead of launch.
- Nominated VYD2311 as next SARS-CoV-2 mAb candidate; expects streamlined FDA development pathway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312524079597/0001193125-24-079597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312524079597/d803546d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-079597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer